4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
China Isotope & Radiation Corporation (1763) operates in the Medical Devices industry and is headquartered in Beijing, China with about 3,578 employees. Its market capitalization is roughly CNY 6 billion. In the fiscal year ended 2025-12-31, 1763 reported CNY 7.2B in revenue and CNY 327M in net income.
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 7.2B | CNY 7.6B | CNY 6.6B | CNY 6.2B | — |
| Gross Profit | CNY 3.6B | CNY 3.7B | CNY 3.5B | CNY 3.5B | — |
| Operating Income (EBIT) | CNY 1.0B | CNY 1.1B | CNY 804M | CNY 896M | — |
| Net Income | CNY 327M | CNY 407M | CNY 371M | CNY 392M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (CNY 125M) | (CNY 123M) | (CNY 141M) | (CNY 121M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 15.7B | CNY 14.8B | CNY 13.2B | CNY 11.8B | — |
| Total Liabilities | CNY 7.6B | CNY 7.0B | CNY 6.1B | CNY 5.2B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1763 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms